Current Rating and Its Significance
MarketsMOJO’s 'Hold' rating for Strides Pharma Science Ltd indicates a balanced stance on the stock, suggesting that investors should neither aggressively buy nor sell at this juncture. This rating reflects a moderate outlook, where the stock exhibits certain strengths but also faces challenges that temper enthusiasm. The 'Hold' grade is supported by a Mojo Score of 51.0, which places the stock in a neutral zone, signalling neither strong bullish nor bearish momentum.
Quality Assessment
As of 19 August 2026, Strides Pharma Science Ltd’s quality grade is assessed as average. The company demonstrates steady operational performance, with positive results reported for the last 12 consecutive quarters. Operating profit has grown at an annual rate of 27.28%, highlighting robust earnings growth. However, the company’s ability to service debt remains a concern, with a Debt to EBITDA ratio of 1.90 times, indicating relatively high leverage. This elevated debt level constrains long-term growth prospects and adds financial risk, which investors should monitor closely.
The company’s return on equity (ROE) averages 9.60%, reflecting modest profitability relative to shareholders’ funds. While this is not a standout figure, it suggests the company is generating reasonable returns but has room for improvement in capital efficiency.
Valuation Perspective
Strides Pharma Science Ltd’s valuation is currently very attractive. The stock trades at a discount compared to its peers’ historical valuations, supported by a low Enterprise Value to Capital Employed ratio of 2.2. The company’s return on capital employed (ROCE) stands at 15.5%, which is healthy and indicative of efficient capital utilisation. This valuation appeal is further underscored by a price-to-earnings-to-growth (PEG) ratio of 0.3, signalling that the stock’s price is low relative to its earnings growth potential.
Over the past year, the stock has delivered a return of 8.90%, while profits have surged by 53.4%, demonstrating that earnings growth has outpaced share price appreciation. This divergence suggests potential upside if the market recognises the company’s improving fundamentals more fully.
Financial Trend Analysis
The financial trend for Strides Pharma Science Ltd is positive. The company reported a profit after tax (PAT) of ₹441.96 crores for the nine months ended, growing at an impressive rate of 46.84%. Operating cash flow for the year reached a peak of ₹702.52 crores, reflecting strong cash generation capabilities. Additionally, the half-year ROCE of 17.96% marks a high point, signalling efficient use of capital in recent periods.
Despite these encouraging trends, the company’s net sales have grown at a more modest annual rate of 9.20% over the last five years, indicating that revenue expansion is steady but not spectacular. Investors should weigh this steady top-line growth against the strong profitability and cash flow improvements.
Technical Outlook
From a technical standpoint, the stock is mildly bearish. Recent price movements show a decline of 0.15% on the day, with a one-month drop of 12.40% and a three-month decline of 18.16%. However, the six-month and year-to-date returns remain positive at 8.65% and 4.64% respectively, suggesting some resilience in the medium term. The mild bearish technical grade advises caution, as short-term price pressures could persist, but the longer-term trend remains cautiously optimistic.
Risks to Consider
One notable risk factor is the high proportion of promoter shares pledged, currently at 38.1%. This level of pledged shares has increased by 10.83% over the last quarter. In volatile or falling markets, high pledged shareholding can exert additional downward pressure on the stock price, as promoters may be forced to liquidate holdings to meet margin calls. This factor adds a layer of risk that investors should factor into their decision-making process.
Summary for Investors
In summary, Strides Pharma Science Ltd’s 'Hold' rating reflects a stock with solid earnings growth, attractive valuation, and positive financial trends, balanced against moderate quality concerns and technical caution. The company’s strong profitability and cash flow generation are encouraging, but leverage and pledged promoter shares introduce risk elements that temper the outlook.
For investors, this rating suggests maintaining existing positions while monitoring developments closely. The stock may offer value for those seeking exposure to pharmaceuticals and biotechnology with a medium-term horizon, but it is not currently a compelling buy or sell candidate based on the latest data.
Built for the long haul! Consecutive quarters of strong growth landed this Small Cap from Chemicals on our Reliable Performers list. Sustainable gains are clearly ahead!
- - Long-term growth stock
- - Multi-quarter performance
- - Sustainable gains ahead
Looking Ahead
Investors should continue to track Strides Pharma Science Ltd’s quarterly earnings and cash flow reports, paying particular attention to debt servicing metrics and promoter share pledging trends. Any improvement in debt ratios or reduction in pledged shares could enhance the stock’s outlook and potentially shift the rating in future assessments.
Moreover, the company’s ability to sustain its operating profit growth and convert this into consistent net sales expansion will be critical for long-term value creation. Given the current valuation attractiveness, the stock remains a candidate for investors seeking exposure to the pharmaceuticals sector with a moderate risk appetite.
Conclusion
Strides Pharma Science Ltd’s 'Hold' rating by MarketsMOJO, last updated on 27 July 2026, reflects a nuanced view of the company’s prospects as of 19 August 2026. The stock offers a blend of solid financial performance and valuation appeal, offset by leverage concerns and technical caution. Investors are advised to maintain a watchful stance, balancing the company’s growth potential against inherent risks in the current market environment.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
